Earkart Limited announced that its Board of Directors has approved two major strategic acquisitions during a meeting held on 11 March 2026. The decisions mark significant expansion moves for the company as it seeks to strengthen its manufacturing capabilities and enter the pharmaceutical sector.

Board Meeting Outcomes

The board meeting, conducted under Regulations 30 and 42 of SEBI Listing Regulations, addressed critical business expansion initiatives. The session ran from 11:30 AM to 1:20 P.M., with directors deliberating on strategic acquisition opportunities.

Strategic Acquisitions Approved

The board approved two key acquisitions that will expand Earkart Limited's operational footprint. The first involves acquiring land specifically designated for establishing a new manufacturing facility, which will enhance the company's production capabilities. The second approval covers the acquisition of a pharmaceutical business, representing the company's strategic entry into the healthcare sector.

Compliance Acknowledgment

Earkart Limited acknowledged that the board meeting was convened on shorter notice due to the urgent nature of matters requiring immediate attention. Company Secretary Preeti Srivastava clarified that the necessary intimation to BSE, as required under Regulation 29 of SEBI LODR Regulations, was not provided within the stipulated timeframe.

The company emphasized that the delay in intimation was solely due to the urgency of matters and not due to compliance oversight. Management assured stakeholders that necessary steps are being implemented to ensure such delays do not occur in future proceedings.

Corporate Governance

The company maintains its commitment to adhering to SEBI compliance requirements and has requested BSE to take the clarification on record. All meeting outcomes and related documentation will be made available on the company's website at https://earkart.com for stakeholder reference.

Company Secretary Preeti Srivastava, with membership number A31615, signed the regulatory filings digitally on 11 March 2026, ensuring proper documentation of the board decisions and compliance clarifications.

Earkart Limited has successfully incorporated a wholly owned subsidiary in the United States as part of its strategic expansion into the American hearing-care market. The company informed BSE Limited about this development through a regulatory filing under Regulation 30 of the SEBI Listing Regulations on 26th February 2026.

Subsidiary Incorporation Details

The new subsidiary, Earkart Inc., was incorporated in Delaware on 20th January 2026 through Corporate Bylaws. The company subsequently received its Employer Identification Number (EIN) on 20th February 2026, completing the formal incorporation process.

Share Structure and Ownership

Earkart Inc. has been authorized to issue 1,000 shares of common stock with a par value of $0.1 per share. Earkart Limited has fully subscribed to all 1,000 shares, maintaining 100% ownership of the subsidiary. The parent company will pay the subscription amount in cash for the shares.

Business Objectives and Operations

The subsidiary will operate in the hearing-care and audiology sector, focusing on the development and scaling of compliant remote audiology services in the United States. Earkart Inc.'s business scope encompasses multiple aspects of hearing healthcare delivery and product distribution.

Key Business Activities:

• Developing and operating compliant remote audiology platforms
• Providing accurate hearing tests and professional audiology services
• Hearing aid fitting, distribution, and sales of affordable hearing aids
• Offering related digital health solutions
• Partnering with ENT and audiology clinics, insurers, pharmacies, and large retailers
• Trading, manufacturing, marketing, and distribution of ear-health and hearing-protection products

Strategic Significance

The incorporation of Earkart Inc. represents a significant step in Earkart Limited's international expansion strategy. According to the company's filing, the wholly owned subsidiary will play a crucial role in advancing the holding company's business expansion in the United States hearing-care market.

The subsidiary's registered office is located at 16192 Coastal Highway, Lewes, Delaware, with Harvard Business Services, Inc. serving as the registered agent. The Certificate of Incorporation was signed by Michael J. Bell, President of Harvard Business Services, Inc., acting as the incorporator.

This development positions Earkart Limited to tap into the American hearing-care market through its dedicated US entity, potentially enabling better market penetration and compliance with local regulations in the healthcare sector.